{
    "code": "52026592",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=52026592",
    "time": "2021-04-09 05:14:03",
    "許可證字號": "衛部藥輸字第026592號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "製造許可登錄編號": "",
    "有效日期": "114\/09\/16",
    "發證日期": "104\/09\/16",
    "許可證種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "通關簽審文件編號": "DHA05202659201",
    "中文品名": "索華迪400毫克膜衣錠",
    "英文品名": "SOVALDI 400mg film-coated tablets",
    "適應症": "成人患者：SOVALDI與其他藥物併用可以治療患有慢性C型肝炎病毒(HCV)感染症的成人患者。\r\n•\t與pegylated interferon及ribavirin併用可治療未併有肝硬化或併有代償性肝硬化的基因型1或4感染症。\r\n•\t與ribavirin併用可治療未併有肝硬化或併有代償性肝硬化的基因型2或3感染症。\r\n兒童患者：SOVALDI與ribavirin併用可治療12歲(含)以上或體重至少35公斤以上，且未併有肝硬化或併有代償性肝硬化之兒童患者的慢性HCV基因型2或3感染症。",
    "劑型": "116膜衣錠",
    "包裝": "28錠塑膠瓶裝(HDPE)",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "06須由醫師處方使用",
    "管制藥品分類級別": "",
    "藥品分類": "",
    "監視期限": "109\/09\/16",
    "主成分略述": "Sofosbuvir",
    "限制項目": "02輸　入 51免除銜接性臨床試驗",
    "申請商名稱": "620117L277  香港商吉立亞醫藥有限公司台灣分公司",
    "申請商地址": "臺北市信義區松仁路32號10樓之1、36號10樓之1",
    "主製造廠": [
        {
            "製造廠名稱": "FIE0060000  GILEAD SCIENCES IRELAND UC",
            "製造廠廠址": "IDA BUSINESS &amp; TECHNOLOGY PARK, CARRIGTOHILL COUNTY CORK, IRELAND",
            "製造廠公司地址": "",
            "製造廠國別": "IRELAND",
            "製程": ""
        }
    ],
    "CCC號列": "",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "0818004800",
            "成分名稱": "Sofosbuvir",
            "含量描述": "",
            "含量": "400.0000000000",
            "單位": "MG"
        }
    ],
    "仿單外盒": [
        {
            "title": "0108-SOVALDI索華迪膜衣錠 400毫克 中文仿單-29.7x66cm-110-02-02.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52026592&Seq=007&Type=9"
        }
    ]
}